These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review. Maqsood MH; Tameez Ud Din A; Khan AH Cureus; 2019 Jan; 11(1):e3986. PubMed ID: 30972265 [TBL] [Abstract][Full Text] [Related]
3. Gastroenteropancreatic Neuroendocrine Tumors. Cives M; Strosberg JR CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930 [TBL] [Abstract][Full Text] [Related]
5. Real-world comparison of healthcare resource utilization and costs of [ Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254 [TBL] [Abstract][Full Text] [Related]
6. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of lutetium ( Palmer J; Leeuwenkamp OR World J Clin Cases; 2020 Oct; 8(20):4793-4806. PubMed ID: 33195647 [TBL] [Abstract][Full Text] [Related]